Skip to content
10-Q

Quarterly Report

Immunoclin Corp

0001517126-14-000031

← back to feed
Filed
Jan 21, 2014 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2013 · Jan 20, 2014 10.36M sh
Operating Cash Flow Q3 2013 · Nov 30, 2013 −$38.11K
Operating Cash Flow Q3 2013 · Nov 30, 2012 −$7.67K
Stockholders Equity Q3 2013 · Nov 30, 2013 $460.1K
Stockholders Equity Q3 2013 · Feb 28, 2013 −$65.77K
Total Liabilities Q3 2013 · Nov 30, 2013 $89.3K
Total Liabilities Q3 2013 · Feb 28, 2013 $65.8K
Total Assets Q3 2013 · Nov 30, 2013 $549.4K
Total Assets Q3 2013 · Feb 28, 2013 $33
Sga Expense Q3 2013 · Nov 30, 2013 $4.22K
Sga Expense Q3 2013 · Nov 30, 2013 $13.31K
Sga Expense Q3 2013 · Nov 30, 2012 $413
Sga Expense Q3 2013 · Nov 30, 2012 $2.37K
Net Income Q3 2013 · Nov 30, 2013 −$64.81K
Net Income Q3 2013 · Nov 30, 2013 −$175.65K
Net Income Q3 2013 · Nov 30, 2013 −$266.68K
Net Income Q3 2013 · Nov 30, 2012 −$5.71K
Net Income Q3 2013 · Nov 30, 2012 $5.25K
Operating Income Q3 2013 · Nov 30, 2013 −$64.74K
Operating Income Q3 2013 · Nov 30, 2013 −$175.57K
Operating Income Q3 2013 · Nov 30, 2013 −$306.11K
Operating Income Q3 2013 · Nov 30, 2012 −$5.71K
Operating Income Q3 2013 · Nov 30, 2012 −$34.25K